Solasta Ventures
VC Fund
Boston, United States
Solasta Ventures is a VC fund in Boston focused on Biotechnology and Health Care. Solasta Ventures is investing in healthcare and life sciences for a brighter future.
- Total investments:
- 37
- Last investment:
- Lead investor:
- 5%
Last updated:
For AI agents: llms.txt
Industries Solasta Ventures invests in
Stages Solasta Ventures invests in
Countries Solasta Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Carl Choi
|
|||
Michael Jeon
|
|||
Nia Julian
|
|||
William Hahn
|
Investment Focus
Industry
- Biotechnology 21 (57%)
- Health Care 18 (49%)
- Therapeutics 16 (43%)
- Medical 8 (22%)
- Biopharma 5 (14%)
Stage
- Series B 12 (32%)
- Series A 7 (19%)
- Series C 6 (16%)
- Funding Round 4 (11%)
- Post-IPO Equity 3 (8%)
Country
- United States 27 (73%)
- Canada 1 (3%)
- New Zealand 1 (3%)
- South Korea 1 (3%)
- United Kingdom 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Carl Choi
Prinipal
|
Prinipal | Total investments: 0 | Find email | |
Derek Yoon
President & CEO
|
President & CEO | Total investments: 0 | Find email | |
|
Michael Jeon
Managing Partner
|
Managing Partner | Total investments: 1 | Find email | |
|
Nia Julian
Executive Assistant
|
Executive Assistant | Total investments: 0 | Find email | |
|
William Hahn
Chair & Scientific Advisory Board
|
Chair & Scientific Advisory Board | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Summer Robotics
|
Summer Robotics is a machine vision company that builds robotic perception software for the industrial manufacturing and mobility markets.Summer Robotics has developed a perception platform that enables robots to work in more complex and fast moving environments than previously possible. We are working with established partners to build the nextgeneration of robotic measurement and manufacturing capabilities that will significantly improve quality and productivity. Summer Robotics' mission is to give all robotic systems superhuman perception and response capabilities, enabling entirely new and valuable applications in markets such as manufacturing and mobility. | Series A / Sep 30, 2025 | |
Ensoma
|
Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As aresult, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited. | $53M / Sep 22, 2025 | |
Maxion Therapeutics
|
Maxion Therapeutics helps in learning transformative therapies. It uses this technology to deliver long-acting, safe, and effective medications against previously inaccessible targets. | $75.3M / Series A / Mar 17, 2025 | |
Axonis Therapeutics
|
Axonis translates breakthrough regeneration research to groundbreaking paralysis therapy, to transform the lives of spinal cord injury patients. | $115M / Series A / Oct 30, 2024 | |
DAAN Biotherapeutics
|
DAAN Biotherapeutics develops novel treatments for cancer patients. The company conducts cancer treatment research and development, including cell therapies, antibodies, and small molecule inhibitors. | $17.2M / Series A / Jan 25, 2024 | |
EvolveImmune Therapeutics
|
EvolveImmune Therapeutics transforms the discovery and development of novel immunotherapies. By leveraging its proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates against numerous targets that are expressed on multiple immune cell types. The company’s platform will generatefirst-in-class treatments for unmet needs in oncology and autoimmune diseases. | $37.4M / Venture - Series Unknown / Nov 16, 2023 | |
ReCode Therapeutics
|
ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and developfirst-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations.ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing.The company was founded in 2015 and is based in Dallas, Texas. | $50M / Series B / Sep 19, 2023 | |
Boxhub
|
Boxhub combines e-commerce and logistics, revolutionizing the way shipping containers are traded, transported, and used. By leveraging tech infrastructure and automation, we make the experience for our customers and suppliers faster, cheaper, and more transparent. | $12.4M / Series A / Jun 28, 2023 | |
Prime Roots
|
Feeding people and the planet with 100% plant-based powerhouse protein! Joshua Nixon and Kimberlie Le founded Terramino in 2017 that later became Prime Roots. It has its headquarters in Berkeley, California. | $30M / Series B / May 15, 2023 | |
|
Prime Roots
|
Feeding people and the planet with 100% plant-based powerhouse protein! Joshua Nixon and Kimberlie Le founded Terramino in 2017 that later became Prime Roots. It has its headquarters in Berkeley, California. | $30M / Series B / May 15, 2023 | |
| See all 37 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Solasta Ventures invest in?
Solasta Ventures invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series A stage. Most of the 37 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Solasta Ventures?
Public channels for Solasta Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Solasta Ventures?
The team at Solasta Ventures includes Carl Choi (Prinipal), Derek Yoon (President & CEO) and Michael Jeon (Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
